Immunotherapy Research for Glioblastoma
The National Cancer Institute reports that "several immunotherapies have shown promise against glioblastoma, including some that have produced long-lasting responses in patients with advanced disease....[A]t least three immunotherapies are in phase III clinical trial, the results of which may form the basis for Food and Drug Administration (FDA) approvals." Read the National Cancer Institute research summary here: "With Immumotherapy, Glimmers of Hope against Gliobastoma," December 9, 2015.
Interested in becoming a sponsor?
Contact us today.